Navigation Links
VCU Massey first to combine targeted agents to kill multiple myeloma cells
Date:2/10/2011

Richmond, Va. (Feb. 10, 2011) Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.

Multiple myeloma is a cancer involving antibody-producing cells in the bone marrow, and, in most cases, is incurable. Targeted therapies work by interfering with biological and biochemical functions critical for cancer cell survival and proliferation. The new treatment strategy from VCU Massey combines Src inhibitors, which block the activity of an important group of proteins that regulate cancer cell behavior, with Chk1 inhibitors, which interfere with cancer cells' ability to undergo cell cycle arrest and repair DNA damage.

"Chk1 inhibitors are currently used primarily in conjunction with conventional DNA-damaging chemotherapeutic agents," says the study's lead investigator Steven Grant, M.D., associate director for translational research, Shirley Carter and Sture Gordon Olsson Chair in Oncology Research and professor of internal medicine at VCU Massey Cancer Center. "By combining Chk1 inhibitors with another targeted agent, such as Src inhibitors, we were able to induce cell death in multiple myeloma cells while sparing healthy, normal cells."

When multiple myeloma cells are subjected to DNA-damaging agents, or even when they are undergoing normal DNA replication, their DNA is subject to breakage. To survive, they must slow down their progression through the cell cycle in order to repair the DNA, or, if the damage is too severe, undergo a form of cell suicide.

Chk1 is an enzyme that allows cells to undergo cell cycle arrest, a process required to repair the DNA damage. When cancer cells are exposed to Chk1 inhibitor
'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
2. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
3. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
4. VCU Massey research finds new link between inflammation and cancer
5. When first-time mothers are induced, breaking the amniotic membrane shortens delivery time
6. First Look at Prostate Cancer Genome Yields Insights
7. First Lady Says President Obama Has Quit Smoking
8. FDA Approves First Pacemaker Deemed Safe During MRIs
9. FDA Approves First Drug to Prevent Premature Births
10. HPV vaccine works for boys: Study shows first clear benefits
11. UofL awarded $9.56 million to form first-ever multicenter cardiovascular research network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for ... elbow injuries, according to new research released today at the ... Day. , “Our findings indicate that a 10 inch increase ... of a history of injury, a 10 mile per hour ... of a history of injury, and playing for more than ...
(Date:3/28/2015)... How best to treat and recover ... orthopaedic medicine. While diagnostic hip injections are commonly performed ... etiology, research presented today at the American Orthopaedic Society ... that pain relief from this diagnostic injection may not ... “Our study looked to assess if the amount of ...
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
Breaking Medicine News(10 mins):Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2
... ... ... WASHINGTON , March 17 The following is a statement by ... , , ...
... , TAMPA, Fla. , March 17 ... features to enhance its acclaimed study program for the ... exams. Effective immediately, 30 animated muscle tutorials, 25 interactive study ... nationwide. These features, which include narration for auditory learners, further ...
... understanding of the Skp2 gene and its relation to cellular ... can suppress tumor development in common types of cancer, researchers ... and Memorial Sloan-Kettering Cancer Center report in the journal ... cycle regulation, cell proliferation, cell growth and the formation of ...
... potentially deadly infections long has focused on looking for ways ... University of Utah and Utah State University shows that modulating ... save more lives. In a study published March ... U of U cardiologist Dean Y. Li, M.D., Ph.D., professor ...
... an indicator of more serious disease, study finds , ... bowel syndrome (IBS) aren,t at increased risk for polyps, ... disease and, in most cases, don,t require a colonoscopy, ... 10 percent to 20 percent of Americans, include recurrent ...
... WHEATON, Ill. , March 17 ... Organizational Planning, John Brady , DHA, has been ... with Disabilities Task Force. The Task Force is responsible ... changes, recommendations, and innovations may be needed to enhance ...
Cached Medicine News:Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 2Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 2Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 4Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 5Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 6Health News:Disabling Skp2 gene helps shut down cancer growth 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 3Health News:Colonoscopy Not Needed for Most With Irritable Bowel Syndrome 2Health News:Marianjoy Vice President Named to Illinois' Disabilities Task Force 2
(Date:3/27/2015)... Calif. , March 27, 2015 The ... life of myeloma patients while working toward prevention and ... (D-NY) for introducing a federal resolution (H. Res. ... March 2015 as "National Multiple Myeloma Awareness Month." ... with myeloma worldwide, and more than 110,000 new cases ...
(Date:3/27/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... focused on oncology with an emphasis on the ... the reporting of data from a single -center ... with the Delcath Hepatic Delivery System (Melphalan/HDS) and ... Society of Surgical Oncology (SSO) Annual Meeting 2015.  ...
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... /PRNewswire-Asia/ -- Synutra International, Inc. (Nasdaq: SYUT ... a producer, marketer and seller of nutritional products for ... will present at Citi,s Greater China Investor Conference to ... Macau.  Management is currently scheduled to meet with institutional ...
... one of the leading clinical trial procurement companies, is ... Clinical Trials Supplies: The New GCPs - Good Clinical ... Coast Conference in Philadelphia, Pennsylvania at the Hilton Philadelphia ... on Wednesday October 20th, and a link to register ...
Cached Medicine Technology:Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference 2Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference 3
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L)....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
For the quantitative determination of Glucose in serum. Endpoint Reaction Product measured at 520 nm. Linearity: 500 mg/dl....
For the quantitative determination of Glucose in serum. Endpoint reaction (NAD -> NADH) measured at 340 nm. Linearity: 600 mg/dl. Liquid working reagent prepared with simple 1:9 dilution....
Medicine Products: